Compare IDXX & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDXX | BDX |
|---|---|---|
| Founded | 1983 | 1897 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.4B | 43.0B |
| IPO Year | 1996 | 1998 |
| Metric | IDXX | BDX |
|---|---|---|
| Price | $549.87 | $189.78 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 13 |
| Target Price | ★ $721.67 | $186.00 |
| AVG Volume (30 Days) | 599.8K | ★ 1.8M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 2.89% |
| EPS Growth | ★ 22.59 | N/A |
| EPS | ★ 7.74 | 1.59 |
| Revenue | $4,303,702,000.00 | ★ $21,840,000,000.00 |
| Revenue This Year | $10.88 | N/A |
| Revenue Next Year | $8.59 | $3.02 |
| P/E Ratio | ★ $72.29 | $119.96 |
| Revenue Growth | ★ 10.42 | 8.24 |
| 52 Week Low | $518.55 | $140.11 |
| 52 Week High | $769.98 | $213.08 |
| Indicator | IDXX | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 46.05 | 68.15 |
| Support Level | $536.34 | $141.69 |
| Resistance Level | $583.93 | $196.05 |
| Average True Range (ATR) | 15.60 | 4.24 |
| MACD | -2.45 | 0.35 |
| Stochastic Oscillator | 23.60 | 73.22 |
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.